加速康复外科在自体乳房再造中的财务影响
该回顾性研究纳入2017年7月至2022年6月共264例连续自体乳房再造患者(ERAS实施前156例、实施后108例),比较临床结局与财务指标。结果显示ERAS组平均住院日和ICU住院日更短,总收费、总成本、直接成本和间接成本均更低,直接利润率更高,而估算报销额无显著差异。
要点
- ERAS组平均住院日2.13天 vs 3.21天,ICU住院日0.0天 vs 0.75天。
- ERAS组总收费$98,876 vs $119,568,总成本$25,725 vs $30,972。
- ERAS组直接利润率$11,564 vs $5874,估算报销额无显著差异。
核心结论
- 在自体乳房再造中实施ERAS路径可缩短住院日和ICU使用,并改善财务指标。
研究设计与样本
- 回顾性综述,纳入2017年7月至2022年6月连续自体乳房再造264例,其中ERAS实施前156例、实施后108例。
主要发现
- ERAS组平均住院日2.13天,低于非ERAS组的3.21天(P < 0.001)。
- ERAS组平均ICU住院日0.0天,低于非ERAS组的0.75天(P < 0.001)。
- ERAS组总收费$98,876,低于非ERAS组的$119,568(P < 0.001)。
- ERAS组总成本$25,725、直接成本$15,900、间接成本$9825,均低于非ERAS组的$30,972、$18,823、$12,149(P < 0.001)。
- ERAS组直接利润率$11,564,高于非ERAS组的$5874(P = 0.0015);估算报销额两组无显著差异($27,464 vs $24,697,P = 0.14)。
临床怎么用
- 在自体乳房再造中可考虑实施ERAS路径以缩短住院日和ICU使用并改善财务指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enhanced Recovery After Surgery (ERAS) pathways have become increasingly common in surgery, but the ERAS financial impact on autologous breast reconstruction has not been defined. METHODS: This study performed a retrospective review of consecutive autologous breast reconstructions (July 2017 to June 2022; 264 patients, 156 pre-ERAS implementation and 108 post-ERAS implementation). Clinical outcomes included length of stay (LOS), ICU length of stay (ICU LOS), average daily morphine milligram equivalent (MME) use, and average total MME use. Financial metrics evaluated the total charges, total cost, direct cost, indirect cost, estimated reimbursement, and direct margin. RESULTS: Average LOS was lower in the ERAS cohort (2.13 vs. 3.21 days, P < 0.001). Average ICU LOS was lower in the ERAS cohort (0.0 vs 0.75 days, P < 0.001). Total charges were lower in the ERAS cohort ($98,876 vs. $119,568, P < 0.001). Total cost was lower in the ERAS cohort ($25,725 vs. $30,972, P < 0.001). Direct cost was lower in the ERAS cohort ($15,900 vs. $18,823, P < 0.001). Indirect cost was lower in the ERAS cohort ($9825 vs. $12,149, P < 0.001). Estimated reimbursement was equivalent ($27,464 vs. $24,697, P = 0.14). Direct margin was higher in the ERAS cohort ($11,564 vs. $5874, P = 0.0015). CONCLUSIONS: ERAS pathways in autologous breast reconstruction decrease length of stay, ICU utilization, and improve financial metrics. Further investigations into quality improvements in ERAS warrant investigation.
引用
- DeVito RG, Ke BG, Stephens K, et al. Financial Effect of Enhanced Recovery After Surgery in Autologous Breast Reconstruction. Ann Plast Surg. 2025. PMID: 40459457. doi:10.1097/SAP.0000000000004391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。